|
INCREASES CYCLOSPORIN TOXICITY
|
OESTROGENS DECREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS, ORAL CONTRACEPTIVES, CLOFIBRATES & POSSIBLY OTHER LIPID LOWERING DRUGS INCREASE HEPATIC CHOLESTEROL SECRETION & ENCOURAGE CHOLESTEROL GALL STONE FORMATION & HENCE COUNTERACT THE EFFECTIVENESS OF URSODIOL & LIKE DRUGS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CARBAMAZEPINE INCREASE ITS METABOLISM RESULTING IN REDUCED EFFICACY
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
ANTICOAGULANT EFFECT IS REDUCED
|
GRISEOFULVIN INCREASES RATE OF METABOLISM OF THE DRUG LEADING TO REDUCED PLASMA LEVELS
|
FOLIC ACID DEFICIENCY MAY PRECIPITATE WITH CONCURRENT USE
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS CAUSE INCREASED LEVELS OF CORTICOSTEROID-BINDING GLOBULIN THEREBY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED.SO WITH OESTROGEN THERAPY STEROID DOSE SHOULD BE REDUCED & INCREASED WHEN OESTROGEN IS TERMINATED
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|